2 380

Cited 4 times in

An Open-Label, Rater-Blinded, 8-Week Trial of Bupropion Hydrochloride Extended-Release in Patients with Major Depressive Disorder with Atypical Features

Authors
 H.-J. Seo  ;  B. C. Lee  ;  J.-H. Seok  ;  H. J. Jeon  ;  J.-W. Paik  ;  W. Kim  ;  K.-P. Kwak  ;  C. Han  ;  K.-U. Lee  ;  C.-U. Pae 
Citation
 PHARMACOPSYCHIATRY, Vol.46(6) : 221-226, 2013 
Journal Title
PHARMACOPSYCHIATRY
ISSN
 0176-3679 
Issue Date
2013
MeSH
Adult ; Antidepressive Agents, Second-Generation/administration & dosage ; Antidepressive Agents, Second-Generation/adverse effects ; Antidepressive Agents, Second-Generation/therapeutic use* ; Bupropion/administration & dosage ; Bupropion/adverse effects ; Bupropion/therapeutic use* ; Delayed-Action Preparations/adverse effects ; Depressive Disorder, Major/diagnosis ; Depressive Disorder, Major/drug therapy* ; Female ; Humans ; Male ; Middle Aged ; Psychiatric Status Rating Scales ; Single-Blind Method
Keywords
bupropion XL ; atypical depression ; effectiveness ; remission ; response ; tolerability
Abstract
The present study aimed at investigating the effectiveness and tolerability of -bupropion hydrochloride extended release (XL) in major depressive disorder (MDD) patients with atypical features (AF).51 patients were prescribed bupropion XL for 8 weeks (6 visits: screening, baseline, weeks 1, 2, 4 and 8). The primary efficacy measure was a change of the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version (SIGH-SAD) from baseline to endpoint. Secondary efficacy measures included the SIGH-SAD atypical symptoms subscale, Clinical Global Impression-Severity (CGI-S), Sheehan Disability Scale (SDS) and Epworth Sleepiness Questionnaire (ESQ). Response or remission was defined as ≥50% reduction or ≤7 in SIGH-SAD total scores, respectively, at end of treatment.The HAM-D-29 total score reduced by 55.3% from baseline (27.3±6.5) to end of treatment (12.2±6.3) (p<0.001). Atypical symptom subscale scores also reduced by 54.5% from baseline (9.2±3.0) to end of treatment (4.2±2.8) (p<0.001). At the end of treatment, 24.4% (n=10) and 51.2% (n=21) subjects were classified as remitters and responders, respectively. The most frequently reported AEs were headache (13.7%), dry mouth (11.8%), dizziness (9.8%), and dyspepsia (9.8%).Our preliminary study indicates that bupropion XL may be beneficial in the treatment of MDD with atypical features. Adequately powered, randomized, double-blind, placebo-controlled trials are necessary to determine our results.
Full Text
https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0033-1353171
DOI
10.1055/s-0033-1353171
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Psychiatry (정신과학교실) > 1. Journal Papers
Yonsei Authors
Seok, Jeong Ho(석정호) ORCID logo https://orcid.org/0000-0002-9402-7591
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/88859
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links